Imaging small animal models of cancer has become an essential and integral part of cancer research. Evolving imaging technologies have also made available different but complementary imaging methods for assessing underlying biology and mechanisms, improving diagnosis and detection, and monitoring effects of cancer therapies. To take full advantage of this rapidly changing imaging landscape, and to provide a wider spectrum of imaging capabilities and services, a new Integrated Small Animal Imaging Research Resource (iSAlRR) has been established, with substantial resources committed by the UCCCC and the institution, to offer a broad spectrum of imaging modalities and techniques for in vivo imaging of small animals and ex vivo imaging of tissue/organ specimens with improved cost effectiveness and operational efficiency. This new Core Facility includes the following four complementary subcores: 1) the formal Magnetic Resonance Imaging and Spectroscopy (MRIS) Facility supported by the CCSG since 2002;2) the formal Optical Imaging Core Facility (OICF), a developing UCCCC core during the current cycle;3) a new microPET/SPECT/CT imaging facility;and 4) a reorganized Imaging Veterinary Technology support subcore (IVT) extracted from the formal MRIS Facility with an expanded mission of providing veterinary support to all animal imaging operations. The core leadership has been enhanced with new scientific co-directors and technical directors with expertise in molecular imaging. The MRIS replaced the old 4.7T magnet with a new 9.4T Bruker system and subsequently acquired additional gradient coils, amplifier, software upgrades to increase image resolution and usage efficiency. The OICF acquired a new Xenogen IVIS Spectrum system to be used outside the animal barrier, while placing the original Xenogen IVIS 200 system behind the barrier to expand the user access. The microPET/SPECT/CT imaging services and capabilities have been established with a Gamma Medica tri-modality pre-clinical imaging system. This new iSAIRR has already demonstrated its broad usage and applications in advancing research in breast, lung, prostate, ovarian, head and neck, pancreatic, colorectal, and brain cancer. Future expansion to enhance quantitative multi-modality imaging methodologies including those in ultrasound and EPRI (electron paramagnetic resonance imaging) will complement the existing MRIS, optical imaging, PET, SPECT, and CT services and capabilities.

Public Health Relevance

This Integrated Small Animal Imaging Research Resource provides a broad range of imaging services to support cancer researchers in using animal models to investigate cancer biology and to develop novel diagnostics and therapeutics. These animal imaging services and capabilities will accelerate cancer research saving in time and resources, thus improving the effective delivery of health care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-38
Application #
8486636
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-23
Budget End
2014-03-31
Support Year
38
Fiscal Year
2013
Total Cost
$114,335
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188
An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Showing the most recent 10 out of 668 publications